Jaguar Health Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

JAGX$0.44+7.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements Of Operations


	Three Months Ended
	March 31,
(In thousands, except share and per share data) · 2024 · 2023
Product revenue, net		$2,351	$1,972
Operating expenses
Cost of product revenue		430	345
Research and development		4,312	4,775
Sales and marketing		1,443	1,884
General and administrative		4,381	4,813
Total operating expenses		10,566	11,817
Loss from operations		(8,215)	(9,845)
Interest expense		(611)	(2,181)
Change in fair value of freestanding and hybrid financial instruments designated at Fair Value Option		(2,021)	(359)
Gain on extinguishment of debt		1,245	—
Other income (expense)		234	(12)
Loss before income tax		(9,368)	(12,397)
Income tax expense		—	—
Net loss		(9,368)	(12,397)
Net loss attributable to noncontrolling interest		$(142)	$(195)
Net loss attributable to common stockholders		$(9,226)	$(12,202)
Net loss per share, basic		$(0.06)	$(2.39)
Net loss per share, diluted		$(0.06)	$(2.39)
Weighted-average common stock outstanding, basic		158,842,297	5,109,609
Weighted-average common stock outstanding, diluted		158,842,297	5,109,609

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.